AKT1 and posterior cortical atrophy: The results revealed that PCa patients in the high-risk group were more susceptible to bryostatin.1, docetaxel, gefitinib, methotrexate, paclitaxel, and vinblastine, whereas patients in the low-risk group benefited more from AKT inhibitor VIII, bexarotene, bicalutamide, doxorubicin, gemcitabine, and vinorelbine.